No, not on a standard test. The immunoassay antibodies built into standard 5 panel, 10 panel, and 12 panel drug testing cups and dip cards target THC, cocaine metabolite, opiates, amphetamines, PCP, and similar drug classes. None of them are built to recognize ketamine or its main metabolite, norketamine. Catching ketamine use requires a dedicated KET (ketamine) screening device, or laboratory confirmation testing.
That gap matters more than it used to. Ketamine is a Schedule III controlled substance with a long-standing, FDA-approved use as a surgical anesthetic, and a newer one: esketamine, sold as Spravato, is FDA-approved for treatment-resistant depression under a restricted federal monitoring program. Off-label ketamine clinics have also expanded, and diverted or recreational use draws ongoing public health attention, none of which shows up on a general drug screen. This guide covers why standard panels miss ketamine, how KET panels work, how long ketamine and its metabolite stay detectable, and why screening demand is rising.
Why Standard Multi-Panel Tests Do Not Catch Ketamine
Rapid urine drug test cups and dip cards work through immunoassay technology. Each strip contains antibodies engineered to bind to one drug or drug class. Standard cups are built around THC, cocaine metabolite, opiates, amphetamines, PCP, and related compounds, the analytes most workplace and clinical programs have historically needed. Ketamine belongs to a separate chemical family, the arylcyclohexylamines, and according to the pharmacology reference maintained on the National Institutes of Health's NCBI Bookshelf, it is metabolized in the liver primarily by the CYP3A4 enzyme into norketamine, its major active metabolite. That structure does not trigger a positive result on antibodies built for THC, cocaine, opiates, amphetamines, or PCP, so a person using ketamine, recreationally, illicitly, or through an unreported clinic visit, can pass a standard panel every time.
Ketamine itself is not new. The Drug Enforcement Administration classifies ketamine, its salts, isomers, and salts of isomers as a Schedule III non-narcotic controlled substance under the federal Controlled Substances Act, reflecting both its legitimate medical use and its recognized abuse potential. That dual status is exactly why leaving it off standard panels has become a bigger issue.
What a Dedicated KET Panel Actually Detects
A ketamine-specific screening device works like any other immunoassay drug test: a monoclonal antibody engineered against ketamine competes with the drug in the urine sample, producing a line or digital readout showing whether the concentration is above or below the device's cutoff. Commonly available point-of-care KET immunoassay devices are configured to a cutoff around 1,000 ng/mL, a threshold set by the manufacturer's assay design and validation data, not by any federal drug testing rule. Ketamine is not one of the drug classes covered by the federal workplace drug testing panel used for DOT-regulated programs, so there is no government-set cutoff for it the way there is for THC or amphetamines. Any cutoff on a ketamine device is a device specification, and it can vary by manufacturer.
Employers, clinics, and treatment programs that want ketamine coverage generally add a dedicated KET strip to a base panel or run it as a standalone device. ASC's rapid drug tests and screening kits collection is where that kind of expanded, program-specific screening capability lives.
How Long Ketamine and Norketamine Stay Detectable in Urine
Ketamine clears the body quickly. The NCBI Bookshelf pharmacology reference lists its elimination half-life as roughly 2 to 4 hours, with most of a dose and its metabolites excreted in urine within about 5 days. On a point-of-care immunoassay at a 1,000 ng/mL range cutoff, that means a short detection window for the parent drug, generally 1 to 3 days after use, though results vary with dose, hydration, and metabolism.
Norketamine tends to linger longer, and the window is highly method dependent. A study in the Journal of Analytical Toxicology, indexed on the National Library of Medicine's PubMed database, tracked urine from hospitalized children given a single ketamine dose as an anesthetic. A sensitive gas chromatography-mass spectrometry method detected norketamine for up to 14 days, while a liquid chromatography-based method detected ketamine itself for up to 11 days and norketamine for up to 6 days. Those figures come from laboratory-grade chromatography at low nanogram concentrations, not a point-of-care cutoff test, which is why a sensitive lab method trails a dose far longer than a screening device. The window also varied considerably between individual patients using the same method.
| Test type | Detects ketamine/norketamine | Method | Best use |
|---|---|---|---|
| Standard 5, 10, or 12 panel cup or dip card | No | Immunoassay, targets THC, cocaine, opiates, amphetamines, PCP and similar classes | General pre-employment, random, and DOT-style programs where ketamine is not a stated concern |
| Dedicated KET (ketamine) immunoassay panel | Screens presumptively, yes | Immunoassay, single analyte at a manufacturer-set cutoff (commonly near 1,000 ng/mL), added to or run alongside a base panel | Ketamine clinics, pain management programs, addiction treatment monitoring, and employers with a specific ketamine concern |
| Laboratory confirmation (GC-MS or LC-MS/MS) | Confirms and quantifies, yes | Chromatography paired with mass spectrometry | Confirming any non-negative KET screen before it is treated as a positive result |
Why Ketamine Screening Demand Is Rising
Three trends are converging to push ketamine onto more testing protocols. First, off-label ketamine clinics have grown. The National Institute on Drug Abuse notes that while ketamine itself is not FDA-approved for any mental health condition, dozens of clinics now offer it off-label, under medical supervision, for depression, anxiety, and pain management, so more patients are legitimately receiving ketamine outside a hospital anesthesia setting than in years past.
Second, a genuinely FDA-approved option now exists alongside that off-label market. Esketamine nasal spray, marketed as Spravato, is FDA-approved for treatment-resistant depression and for depressive symptoms in major depressive disorder with acute suicidal ideation, always with an oral antidepressant. Because of sedation, dissociation, and respiratory depression risks, and its own abuse and misuse potential, the FDA-approved prescribing information requires that Spravato be administered only under a healthcare provider's direct observation, with monitoring for at least two hours after each dose, through a restricted program called the Spravato REMS.
Third, diversion and recreational use remain a documented concern. NIDA-funded research cited on the agency's ketamine research page found that poison control center reports involving ketamine increased roughly 81 percent between 2019 and 2021, with the sharpest problems arising when ketamine was combined with opioids or GHB. Ketamine's Schedule III status reflects that same tension: real medical value paired with recognized abuse potential, exactly the profile worth adding to a targeted screening protocol rather than ignoring because it sits outside the standard panel. Pain management programs and addiction treatment centers feel this gap most directly, and ASC's pain management and pain clinic drug testing collection and addiction recovery drug and alcohol testing collection are built for that kind of expanded, condition-specific monitoring.
Legitimate Medical Use and the Role of MRO Review
A non-negative ketamine screen is not proof of illicit use. Ketamine has been an FDA-approved anesthetic since 1970, and esketamine has been FDA-approved for treatment-resistant depression since 2019, administered under direct medical supervision. A patient receiving legitimate Spravato treatment, or one recently given ketamine as a procedural anesthetic, can screen non-negative on a KET panel for entirely appropriate medical reasons.
Because ketamine is not part of the federal drug testing panel used for DOT-regulated programs, ketamine screening typically shows up in employer-added panels, pain clinic monitoring, and treatment center protocols. Any program that adds a KET panel should route non-negative results through the same review used for any other non-negative screen: a Medical Review Officer, or an equivalent clinical reviewer in a non-DOT program, should confirm whether a documented prescription or recent procedure explains the result before it is treated as evidence of misuse.
Confirmation Testing Is Not Optional
Every dedicated KET immunoassay device produces a presumptive, qualitative result, not a confirmed one. Because the antibody-based screen can produce false positives from cross-reacting compounds and cannot quantify the exact concentration present, any non-negative result needs confirmation by gas chromatography-mass spectrometry (GC-MS) or liquid chromatography-tandem mass spectrometry (LC-MS/MS) before it is used for any employment, clinical, or legal decision. ASC's laboratory and reference lab drug testing supplies collection supports that confirmation workflow.
Building a Ketamine Testing Protocol Without Guessing
- Decide who needs it. General pre-employment and DOT-style programs may not need ketamine coverage. Pain clinics, addiction treatment programs, and employers with diversion concerns usually do.
- Start from a reliable base panel. ASC's drug testing cups collection covers standard drug classes, then a KET strip or standalone device adds ketamine-specific coverage.
- Never treat a screen as final. Any non-negative KET result is presumptive and needs lab confirmation plus MRO or clinical review of any documented prescription before anyone acts on it.
- Document the clinical context. Ask about current esketamine treatment or recent anesthesia as part of the review, the same way a program asks about a documented opioid prescription.
- Train collectors and reviewers. A negative standard panel says nothing about ketamine use either way, and staff need to understand that.
Frequently Asked Questions
Does a standard 12 panel drug test detect ketamine?
No. Standard 5, 10, and 12 panel immunoassay cups and dip cards target THC, cocaine metabolite, opiates, amphetamines, PCP, and similar drug classes. Ketamine and its metabolite, norketamine, are not among the analytes those panels are built to detect.
What cutoff level do ketamine urine tests use?
Dedicated KET immunoassay devices commonly use a cutoff near 1,000 ng/mL, but this is a manufacturer-set device specification, not a federal standard. Ketamine is not part of the federal workplace drug testing panel used for DOT-regulated programs, so there is no government-mandated cutoff.
How long does ketamine stay detectable in urine?
On a point-of-care immunoassay at a typical cutoff, the parent drug is generally detectable for roughly 1 to 3 days after use, consistent with its short 2 to 4 hour elimination half-life. Its metabolite, norketamine, can be detected longer using highly sensitive lab chromatography, with published research finding it identifiable for a week or more after a single dose, though results vary by individual.
Does a positive ketamine screen prove someone misused the drug?
No. A non-negative screening result on any immunoassay device, including a ketamine-specific one, is presumptive only. It requires laboratory confirmation by GC-MS or LC-MS/MS, and review of any documented ketamine or esketamine prescription, before it should be treated as evidence of misuse.
Compliance and Accuracy Note
Drug test cups, dip cards, and other screening devices provide presumptive screening results, not a diagnosis. Any non-negative result should be treated as preliminary and confirmed through laboratory testing before any employment, clinical, or legal action. This article is informational only, not medical or legal advice; verify current law and manufacturer specifications, and consult qualified counsel, before implementing a testing policy.
